Poorly Differentiated Thyroid Gland Carcinoma

Poorly Differentiated Thyroid Gland Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

19 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 11
Recruiting: 3
Ph III recruiting: 0
Growth YoY: —
Industry share: 0%
Top sponsor: M.D. Anderson Cancer Center
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (2)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02041260	A Phase II Trial of Cabozantinib for the Treatment of Radioiodine (RAI)-Refractory Differentiated Thyroid Carcinoma (DTC) in the First-line Setting	unknown	Phase 2	43	Thomas Jefferson UniversityOTHER	1	Oct 15, 2021	clinicaltrials
NCT03387943	PLD Combined With Cisplatin in the Treatment of Advanced Poorly Differentiated Thyroid Carcinoma	unknown	Phase 2	30	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.INDUSTRY	1	Jan 3, 2018